Lange Symposium explores synergy between academia and industry
On December 10, at the Joseph Martin Conference Center, the MD-PhD Program at HMS and OTD cohosted the Lange Symposium on Academia-Industry Synergy at the Forefront of Translational Medicine. The Symposium aimed to develop new ideas for synergy between academia and industry to enhance the translation of biomedical discoveries to the clinic as well as expose students and other trainees to cutting edge approaches in experimental therapeutics. Panelists presented their perspectives on coordinating efforts between academia and industry and commented on how their career paths prepared them for a career in translational medicine and therapeutics.
Dean Jeffrey S. Flier, MD, moderated the panel and led an edifying conversation with the experts:
- Peter Kim, PhD, (formerly Merck)
- Michael Vincent, MD, PhD, Pfizer
- Sangeeta Bhatia, MD-PhD, MIT/HMS/BWH
- Peter Sorger, PhD, HMS
- Isaac Kohlberg, Chief Technology Development Officer, Harvard University
The symposium was held in honor of program alum, Lou Lange, MD, PhD, currently General Partner of Asset Management and founder of CV Therapeutics. Following the Symposium, the MD-PhD Program hosted a dinner for its students and other invited guests where Dr. Lange provided personal reflections on his career bridging academia and industry.
Co-sponsorship included HMS Office of Graduate Education and Global Programs, HMS Division of Medical Sciences, and Novartis.